#China #Newark #Biopharma #BIOSeedin

BIOSeedin Innovation Partnering Conference 2025

The BIOSeedin Innovation Partnering Conference (BIOS) held its 5th annual gathering this year, further establishing itself as a pivotal platform in the biopharmaceutical sector since its inception in 2021. This event, hosted by bioSeedin, amassed over 2,000 registrants from 10 nations, attracting leading biotech startups and major investment firms. With a focus on fostering collaboration between China's burgeoning biopharma industry and the global market, BIOS serves to facilitate essential partnerships, therapeutic asset licensing, and investment networking.

The gathering notably saw a significant representation from senior executives and investors, with a remarkable 61.66% of attendees occupying C-suite, business development, or investment roles. A staggering 7,275 meeting requests were recorded, leading to confirmed deals in diverse areas such as oncology and rare diseases. Noteworthy multinational corporations (MNCs) like Merck & Co., Pfizer, and Bayer emerged as key players, receiving over 50 meeting requests each.

Key Insights from BIOS Discussions

Several prominent figures shared their insights during engaging discussions at BIOS. Dr. Yi Zhu, founder and Chief Scientific Officer of Biokin Pharma, pointed out China's unique position as a powerhouse of translational research that can effectively de-risk high-impact modalities. He notably referenced Biokin's innovative Phase II PD-1xLAG-3 bispecific antibody, indicating that China's efficient execution of clinical trials supports rapid validation processes for complex biologics. His call for investors to concentrate on high-risk, high-reward assets resonated with many at the conference, especially considering that Chinese startups now contribute to 38% of global antibody-drug conjugate (ADC) patents.

In a packed session, John Zhu, CEO of DualityBio, challenged the traditional metrics of innovation. "True differentiation isn't merely about novelty but rather about clinical value driven by biomarkers," he declared while highlighting DualityBio's pioneering tumor-activated ADC linker technology. This critique of what he termed 'therapeutic crowding' reflected investor interest in China's advancing precision medicine pipelines.

Dr. Zhang Lianshan, Executive Vice President of Hengrui Pharma, emphasized the need for localization in global initiatives. "Effective globalization begins with domestic validation," he asserted, elaborating on Hengrui's strategic plan to utilize China's comprehensive cancer patient registry of 140 million for accelerated oncology trials. His presentation on a Claudin 18.2-targeted therapy currently in Phase III trials highlighted China's evolution from a follower to a significant contributor in clinical protocol design.

Adding a practical perspective, Jacky Jiang, Business Development Head at CSPC Pharma, outlined an actionable plan for strategic asset curation, emphasizing the need to align research and development with unmet patient needs and technical capabilities. His remarks on non-viral gene therapies, which are expected to dominate investments in rare diseases by 2026, garnered significant attention from investors.

Showcasing Innovation

During the roadshow segment, BIOSeedin 2025 highlighted 40 companies, illustrating China’s accelerating dominance in next-generation therapies. About 40% of the assets presented featured revolutionary modalities like the Phase II PD-1xLAG-3 bispecific for non-small cell lung cancer (NSCLC) and Claudin 18.2xCD3 T-cell engagers. These innovations are a testament to the 32% of global patents held by Chinese firms in these technologies. Additionally, breakthroughs in rare diseases were showcased, including CRISPR-Cas12Max therapies with impressive efficacy in primate models for retinal disorders and gene therapies for Duchenne muscular dystrophy. Metabolic and CNS advancements were also highlighted, demonstrating various dual GLP-1/GIP agonists outperforming competitors in weight-loss trials and tau-targeting monoclonal antibodies for Alzheimer's disease.

As 50% of the showcased programs are in early clinical stages (Phase I/II), including ten assets designated as breakthrough therapies, the portfolio clearly signifies China's transformation into a global innovator in biopharma, merging cost-effective development strategies with an emphasis on patient-centric therapeutic innovation.

Looking ahead, the BIOSeedin 2026 conference promises to expand its international presence, with dedicated forums tailored for European and North American participants. Dr. Yi Zhu concluded the discussions by stating, "China's biotech sector is not merely catching up but is indeed redefining innovation. We invite global partners to embark on this journey, where collaborative efforts transcend borders, paving the way for patient-focused advancements."

For those interested in investment proposals, transformative partnerships, or exploring the future of biopharma innovation, BIOSeedin 2026 promises to be an event not to be missed.

For more information, visit www.bioseedin.com or contact: [email protected]